
MRTX
Healthcare · Biotechnology · $4.12B market cap
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2023
EPS trend, 90 days to now · +10.7% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 4 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 6, 2023 | Before the open | -2.84 | -2.49 | +12.3% |
| Aug 8, 2023 | After the close | -3.17 | -3.04 | +4.1% |
| May 9, 2023 | After the close | -3.55 | -3.18 | +10.4% |
| Feb 28, 2023 | After the close | -3.55 | -3.51 | +1.1% |
| Nov 8, 2022 | After the close | -3.48 | -3.09 | +11.2% |
| Aug 3, 2022 | After the close | -3.49 | -3.18 | +8.9% |
| May 4, 2022 | After the close | -3.49 | -3.40 | +2.6% |
| Feb 28, 2022 | After the close | -3.00 | -3.72 | -24.0% |
| Nov 8, 2021 | After the close | -2.89 | -1.55 | +46.4% |
| Aug 5, 2021 | After the close | -2.40 | -3.23 | -34.6% |
| May 6, 2021 | After the close | -2.13 | -2.67 | -25.4% |
| Feb 25, 2021 | After the close | -2.23 | -2.08 | +6.7% |
| Nov 4, 2020 | After the close | -1.97 | -1.96 |
Mirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. The company provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC), as well as in clinical development as a monotherapy and in combination with…
| +0.5% |
| Aug 6, 2020 | After the close | -2.09 | -1.89 | +9.6% |
| May 7, 2020 | After the close | -1.66 | -2.02 | -21.7% |
| Feb 25, 2020 | Before the open | -1.44 | -1.83 | -27.1% |
| Nov 4, 2019 | After the close | -1.25 | -1.38 | -10.4% |
| Aug 5, 2019 | After the close | -1.20 | -1.26 | -5.0% |
| Apr 29, 2019 | After the close | -0.97 | -1.17 | -20.6% |
| Feb 28, 2019 | After the close | -0.87 | -0.87 | 0.0% |
| Nov 6, 2018 | After the close | -0.87 | -0.85 | +2.3% |
| Aug 1, 2018 | After the close | -0.78 | -0.94 | -20.5% |
| May 7, 2018 | After the close | -0.60 | -0.51 | +15.0% |
| Mar 8, 2018 | After the close | -0.61 | -0.67 | -9.8% |